These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21707532)

  • 1. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
    Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
    Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S; Di Giorgio C; Distrutti E
    Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
    Cipriani S; Mencarelli A; Palladino G; Fiorucci S
    J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
    Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
    Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of farnesoid X receptor agonists.
    Ali AH; Carey EJ; Lindor KD
    Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
    Villalona G; Price A; Blomenkamp K; Manithody C; Saxena S; Ratchford T; Westrich M; Kakarla V; Pochampally S; Phillips W; Heafner N; Korremla N; Greenspon J; Guzman MA; Kumar Jain A
    JPEN J Parenter Enteral Nutr; 2018 Nov; 42(8):1238-1251. PubMed ID: 29701901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FXR modulators for enterohepatic and metabolic diseases.
    Wang H; He Q; Wang G; Xu X; Hao H
    Expert Opin Ther Pat; 2018 Nov; 28(11):765-782. PubMed ID: 30259754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic functions of bile acids mediated by the farnesoid X receptor.
    Stanimirov B; Stankov K; Mikov M
    Acta Gastroenterol Belg; 2012 Dec; 75(4):389-98. PubMed ID: 23402081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.